941 related articles for article (PubMed ID: 30619259)
1. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
Front Immunol; 2018; 9():2874. PubMed ID: 30619259
[TBL] [Abstract][Full Text] [Related]
2. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.
den Brok MH; Büll C; Wassink M; de Graaf AM; Wagenaars JA; Minderman M; Thakur M; Amigorena S; Rijke EO; Schrier CC; Adema GJ
Nat Commun; 2016 Nov; 7():13324. PubMed ID: 27819292
[TBL] [Abstract][Full Text] [Related]
3. Vaccine adjuvants to engage the cross-presentation pathway.
Lee W; Suresh M
Front Immunol; 2022; 13():940047. PubMed ID: 35979365
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.
Tacken PJ; Zeelenberg IS; Cruz LJ; van Hout-Kuijer MA; van de Glind G; Fokkink RG; Lambeck AJ; Figdor CG
Blood; 2011 Dec; 118(26):6836-44. PubMed ID: 21967977
[TBL] [Abstract][Full Text] [Related]
5. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction.
den Brok MH; Nierkens S; Wagenaars JA; Ruers TJ; Schrier CC; Rijke EO; Adema GJ
Vaccine; 2012 Jan; 30(4):737-44. PubMed ID: 22138178
[TBL] [Abstract][Full Text] [Related]
6. Correlates of vaccine adjuvanticity, vaccine activity, protective immunity and disease in human infectious disease and cancer.
Ottenhoff THM
Semin Immunol; 2018 Oct; 39():1-3. PubMed ID: 30318307
[No Abstract] [Full Text] [Related]
7. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
8. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
10. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
Schnurr M; Orban M; Robson NC; Shin A; Braley H; Airey D; Cebon J; Maraskovsky E; Endres S
J Immunol; 2009 Feb; 182(3):1253-9. PubMed ID: 19155470
[TBL] [Abstract][Full Text] [Related]
11. Delivered antigen peptides to resident CD8α
Wang L; Wang Z; Qin Y; Liang W
Eur J Pharm Biopharm; 2020 Feb; 147():76-86. PubMed ID: 31887349
[TBL] [Abstract][Full Text] [Related]
12. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
Maraskovsky E; Schnurr M; Wilson NS; Robson NC; Boyle J; Drane D
Immunol Cell Biol; 2009 Jul; 87(5):371-6. PubMed ID: 19381160
[TBL] [Abstract][Full Text] [Related]
13. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
[TBL] [Abstract][Full Text] [Related]
14. The immunogenicity of CpG-antigen conjugates.
Wagner H
Adv Drug Deliv Rev; 2009 Mar; 61(3):243-7. PubMed ID: 19174176
[TBL] [Abstract][Full Text] [Related]
15. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
16. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.
Schreibelt G; Benitez-Ribas D; Schuurhuis D; Lambeck AJ; van Hout-Kuijer M; Schaft N; Punt CJ; Figdor CG; Adema GJ; de Vries IJ
Blood; 2010 Jul; 116(4):564-74. PubMed ID: 20424184
[TBL] [Abstract][Full Text] [Related]
17. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E
Gierlich P; Lex V; Technau A; Keupp A; Morper L; Glunz A; Sennholz H; Rachor J; Sauer S; Marcu A; Grigoleit GU; Wölfl M; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2020 Jun; 69(6):1029-1042. PubMed ID: 32100075
[TBL] [Abstract][Full Text] [Related]
19. An overview of adjuvant formulations and delivery systems.
García A; De Sanctis JB
APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
[TBL] [Abstract][Full Text] [Related]
20. Boosting vaccine power.
Garçon N; Goldman M
Sci Am; 2009 Oct; 301(4):72-9. PubMed ID: 19780455
[No Abstract] [Full Text] [Related]
[Next] [New Search]
